Browsing by Author "Canillas, Lidia"

Sort by: Order: Results:

  • Clinical guideline on perioperative management of patients with advanced chronic liver disease
    Canillas, Lidia; Pelegrina-Manzano, A.; Álvarez, Juan C.; Colominas-González, Elena; Salar, Antonio; Aguilera, Lluís G.; Burdío Pinilla, Fernando; Montes, Antonio; Grau, Santiago; Grande, Luís; Carrión, José A. (MDPI, 2023)
    (1) Background: Patients with advanced chronic liver disease (ACLD) are living longer with more comorbidities because of improved medical and surgical management. However, patients with ACLD are at increased risk of ...
  • Follow-up evaluation of patients with liver test abnormalities detected during SARS-CoV2 infection
    Canillas, Lidia; Broquetas, Teresa; Carrión Rodríguez, José Antonio; Pagano, Giulia; Soriano, Agnès; Garrido, Esther; Fernández, Rosa; Viu, Ana; Romero, Judit; Díaz,Gemma; Cañete Hidalgo, Nuria; Coll Estrada, Susanna; Naranjo‐Hans, Dolores; Bessa Caserras, Xavier; Garcia-Retortillo, Montserrat; Puigvehí, Marc (Wiley, 2022)
    Abnormal liver function tests (A-LFTs) during admission for coronavirus disease-19 (COVID-19) are frequent, but its evolution after COVID-19 resolution remains unexplored. We evaluated factors related to A-LFTs during ...
  • Hepatitis B surface antigen and hepatitis B core-related antigen kinetics after adding pegylated-interferon to nucleos(t)ids analogues in hepatitis B e antigen-negative patients
    Broquetas, Teresa; Garcia-Retortillo, Montserrat; Micó, Miquel; Canillas, Lidia; Puigvehí, Marc; Cañete Hidalgo, Nuria; Coll Estrada, Susanna; Viu, Ana; Hernández, Juan José; Bessa Caserras, Xavier; Carrión Rodríguez, José Antonio (Baishideng Publishing Group, 2020)
    Background: Hepatitis B e antigen-negative chronic hepatitis B patients under nucleos(t)ids analogues (NAs) rarely achieve hepatitis B surface antigen (HBsAg) loss. Aim: To evaluate if the addition of pegylated interferon ...
  • On-therapy HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg-negative patients. The cup is half full and half empty
    Broquetas, Teresa; Hernández, Juan José; Garcia-Retortillo, Montserrat; Canillas, Lidia; Puigvehí, Marc; Cañete Hidalgo, Nuria; Coll Estrada, Susanna; Viu, Ana; Garrido, Esther; Micó, Miquel; Bessa Caserras, Xavier; Carrión Rodríguez, José Antonio (Elsevier, 2022)
    Background: Nucleos(t)ide analogues withdrawal may improve HBsAg loss rates. However, conditions to select patients are not well established. Aims: to evaluate the impact of HBsAg kinetics before treatment interruption on ...
  • Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma
    Soria, Anna; Calvo, Mariona; Casas, Meritxell; Vidales, Zara; Muñoz-Martínez, Sergio; Sapena, Victor; Puigvehí, Marc; Canillas, Lidia; Guardeño, Raquel; Gallego, Adolfo; Mínguez, Beatriz; Horta, Diana; Clos, Ariadna; Montoliu, Silvia; Roget, Mercè; Reig, María; Vergara, Mercè (Frontiers, 2022)
    Introduction: the first-line treatment for advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab, but its availability is not universal and elderly patients are underrepresented in clinical trials. There ...